MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas
Lauren Stopfer(Io Therapeutics (United States)), Forest M. White(Center for Cancer Research), Shannon L. Winski(Pfizer (United States)), Owen Leddy(University of Chicago), Eric N. Brown(Pfizer (United States)), James A. Wells(University of California, San Francisco), Bryan D. Bryson(Massachusetts Institute of Technology), Joshua M. Mesfin(ETH Zurich), Nicholas J. Rettko(University of California, San Francisco)
Cited by 2
Related Papers
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
|Nature|2013|2.5k
Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae
|Nature Biotechnology|2002|1.6k
How many human proteoforms are there?
|Nature Chemical Biology|2018|945
Time-resolved Mass Spectrometry of Tyrosine Phosphorylation Sites in the Epidermal Growth Factor Receptor Signaling Network Reveals Dynamic Modules
|Molecular & Cellular Proteomics|2005|547